CordVida
- Company typePrivate
- Founded2003
- HeadquartersSão Paulo, Brazil
- Headcount11–50
- GTM typeB2C
- OfferingServices
CordVida firmographics
Firmographics- Name
- CordVida
- Legal name
- Instituto Medicina de Processamento e Armazenamento de Celulas Tronco S.A.
- Website
- https://cordvida.com.br
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
CordVida industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industry
- Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)
Keywords
Where CordVida is headquartered
LocationHeadquarters
- HQ city
- São Paulo
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
CordVida business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Stem Cell Storage Services: CordVida generates revenue through stem cell collection, processing, and long-term storage services for umbilical cord blood and tissue. Revenue is comprised of an initial collection/processing fee and recurring storage fees paid annually or in multi-year plans (2, 5, 10, or 18 years). The company offers combined storage of blood and tissue, which provides up to 20% savings for customers.
- Initial Collection and Processing Fee: One-time fee covering collection procedure, hospital materials, transport, sample testing, and processing required before storage. Fee varies by collection location, whether family is existing customer, if parents are physicians, or if pregnancy is twins.
- Storage Fee: Annual or multi-year storage fees for maintaining cryopreserved stem cells. Multi-year plans offer progressive financial discounts. Fee varies by stem cell type (blood vs. tissue) and storage technology chosen.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual Storage Plan |
| Subscription | Multi-year contract | 2-Year Storage Plan |
| Subscription | Multi-year contract | 5-Year Storage Plan |
| Subscription | Multi-year contract | 10-Year Storage Plan |
| Subscription | Multi-year contract | 18-Year Storage Plan |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
CordVida product offering
Product offeringCore offering
CordVida provides umbilical cord blood and tissue stem cell collection, processing, and long-term cryopreservation services for expectant families. The company operates a specialized laboratory in São Paulo where hematopoietic stem cells from cord blood and mesenchymal stem cells from cord tissue are processed and stored at -196°C in liquid nitrogen tanks. Services include initial collection at hospitals/maternity wards coordinated through a credentialed medical network, laboratory processing and testing, and recurring storage subscriptions lasting from annual terms up to 18 years.
Product overview
CordVida offers a comprehensive cord blood and tissue stem cell banking service with two core biological products: hematopoietic stem cell storage from cord blood (for treatment of blood diseases) and mesenchymal stem cell storage from cord tissue (for regenerative medicine applications). The company operates two distinct storage technologies: Tecnologia Automática® (proprietary fully automated robotic individual storage) and Tecnologia Semiautomática (semi-automated shared rack storage). Additional offerings include the Programa Coleta Solidária for families with medical transplant needs. All samples are cryopreserved at -196°C in liquid nitrogen tanks with 24/7 monitoring and can be shipped worldwide if needed for treatment.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 86% above ANVISA standard cell recovery
- +4 more outcomes
Companies that use CordVida
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
CordVida technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CordVida partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Tissue Regeneration Therapeutics Inc. (TRT)coreCordVida holds the exclusive agreement in Brazil for transferring technology from the Canadian company TRT, which identifies and separates the richest portion of stem cells from cord tissue and stores the tissue entirely. This partnership enables CordVida's tissue stem cell storage service launched in May 2012.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
CordVida competitors and assessment
Company assessmentDirect peers
- Cordlife: Asia-Pacific cord blood banking group with operations across Singapore, Hong Kong, India, and Indonesia. Comparable dual blood/tissue storage offering and multi-year storage plans, with relevant Asia emerging-markets precedent.
- Americord Registry: US private cord blood and tissue bank with combined storage offering and consumer-facing sales channels. Comparable on product scope (blood + tissue) and direct-to-consumer go-to-market.
- Cryo-Cell International: Publicly traded US cord blood bank (ticker CCEL) offering menstrual stem cell and umbilical cord blood/tissue storage services. Comparable in product mix and recurring-revenue subscription model, with the additional benchmark of being a publicly disclosed peer.
- Smart Cells International: UK private cord blood stem cell bank offering collection, processing, and long-term storage for international clients. Comparable subscription-based storage model and physician-channel distribution.
- ViaCord: US private cord blood bank offering umbilical cord blood and cord tissue banking with multi-year storage plans and physician-referral distribution. Closely comparable business model and product structure to CordVida.
- CBR (Cord Blood Registry, now Generate Life Sciences): One of the largest private cord blood banks in the US, offering collection, processing, and long-term cryostorage of cord blood and tissue stem cells. Directly comparable to CordVida on product offering, target customer (expectant families), and multi-year storage revenue model.
- Cells4Life: UK-based private cord blood and tissue bank operating across multiple geographies. Comparable on dual blood-and-tissue storage, multi-year storage plans, and international sample dispatch capabilities.
- StemCyte: US-based hybrid public/private cord blood bank with international operations. Comparable on cryopreservation technology, AABB-accredited operations, and shipment of units for transplant globally.
Regional players
- BCRI (Banco de Células-Tronco do Rio de Janeiro): Brazilian cord blood bank operating in the same domestic market as CordVida with overlapping customer base. Most directly relevant regional competitor for benchmarking Brazilian pricing, share, and physician network dynamics.
Emerging players
- Acorn Biolabs: Canadian cell preservation company focused on non-cord adult stem cell (hair follicle) cryopreservation. Adjacent category — uses similar cryogenic technology and consumer D2C model but targets a different cell source; useful proxy for emerging preservation threats.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CordVida social profiles
Digital presenceCordVida compliance and trust
Trust signalCompliance3 records
CordVida financial estimates
Financial estimateRevenue estimate
Valuation estimate
CordVida leadership team
Management profileNumber of profiles
Profiles6 records
CordVida funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CordVida M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CordVida
What does CordVida do?
CordVida provides umbilical cord blood and tissue stem cell collection, processing, and long-term cryopreservation services for expectant families. The company operates a specialized laboratory in São Paulo where hematopoietic stem cells from cord blood and mesenchymal stem cells from cord tissue are processed and stored at -196°C in liquid nitrogen tanks. Services include initial collection at hospitals/maternity wards coordinated through a credentialed medical network, laboratory processing and testing, and recurring storage subscriptions lasting from annual terms up to 18 years.
Is CordVida a public or private company?
CordVida is a private company. It is classified as corporate owned and is currently operating.
When was CordVida founded?
CordVida was founded in 2003. It employs 11 to 50 people.
Where is CordVida based?
CordVida is headquartered in São Paulo, Brazil, in the Latin America region.
How does CordVida make money?
Three revenue lines are on record. Stem Cell Storage Services are the primary driver. The others are initial Collection and Processing Fee and storage Fee.
Who are CordVida's main competitors?
Direct peers on record are Cordlife, Americord Registry, Cryo-Cell International, Smart Cells International, ViaCord, CBR (Cord Blood Registry, now Generate Life Sciences), Cells4Life and StemCyte. BCRI (Banco de Células-Tronco do Rio de Janeiro) is listed as a regional player. Acorn Biolabs is listed as an emerging player.
Does CordVida have an API?
No public API is recorded for CordVida.
What industry is CordVida in?
CordVida's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAFAMAG, Transfusion Medicine & Immunohematology (Blood Bank). Its NAICS code is 621991.